Surrozen: Innovative Wnt Pathway Targeting and Strategic Partnerships Present Compelling Buy Opportunity
Matthew Caufield, an analyst from H.C. Wainwright, has initiated a new Buy rating on Surrozen (SRZN).Invest with Confidence: Follow TipRanks' ...
Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with 5.9% CAGR | MarketsandMarkets
The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9%, reaching US$ ...
Poultry Medicine/Pharmaceuticals Market to Hit USD 6.68 Billion by 2029 with 5.9% CAGR | MarketsandMarkets™
The poultry medicine/pharmaceuticals market valued at US$ 4.73 billion in 2023, is forecasted to grow at a robust CAGR of 5.9 ...
Warum Zölle für deutsche Pharmaunternehmen besonders hart wären
Die USA sind für Medikamentenhersteller ein überaus attraktiver Markt. Kein Wirtschaftszweig in Deutschland ist so vom ...
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight
DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...
Veterinary Vaccines Market to Hit US$13.33 Billion by 2029 with 6.1% CAGR | MarketsandMarkets
The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, reaching US$9.39 billion ...
Psoriasis Drugs Market To Reach USD 52.34 Billion By 2033, Growing At A 11.50% CAGR
psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...
Global Bovine Tuberculosis Diagnosis Market Increasing Size, Demand, Growth Rate, And Forecast 2033 - Emergen Research
VANCOUVER, BRITISH COLUMBIA, CANADA, January 19, 2025 /EINPresswire / -- The Bovine Tuberculosis (TB) Diagnosis market is expected to grow from USD 781.5 million in 2024 to USD 1.16 billion by 2033, ...
Benefits Pro14d
Ozempic among 15 drugs selected for Medicare drug price talks, Round 2, with Big Pharma
Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, including Pfizer, Novo Nordisk and GlaxoSmithKline.